ReviewResearch (Washington, D.C.)2026
Polyamines as a Universal Language of Host-Microbiota Symbiosis.
Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyamines are ancient metabolites that serve critical functions in maintaining epithelial integrity, regulating immune response, and supporting healthy aging. The gut microbiota actively synthesizes and converts polyamines, while host factors such as inflammation, barrier function, and nutritional status dynamically modulate this metabolic network. Disruption of this host-microbiota axis reduces polyamine availability, impairs barrier function, and exacerbates inflammation. In contrast, polyamines exert protective effects by promoting epithelial repair, modulating macrophage and T-cell responses, and enhancing autophagy-mediated tissue renewal and longevity. Recent advances in engineered probiotics, microbial small RNAs, and postbiotics further highlight the therapeutic potential of precisely modulating polyamine metabolism in clinical contexts such as inflammatory bowel disease, metabolic syndrome, and neurodegenerative conditions associated with aging.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.